Table 4.

Outcome by mutation types and disease phase

Phase/mutation status before second TKI	N	2-year, %
		EFS	OS
CP
None	29	63	96
Mutated low IC50	15	78	100
Mutated intermediate IC50	8	22	70
Mutated high IC50	4	0	75
Mutated unknown IC50	3	67	100
P*		<.001	.03
AP
None	30	27	49
Mutated low IC50	21	9	60
Mutated intermediate IC50	10	11	42
Mutated high IC50	4	0	50
Mutated unknown IC50	6	84	80
P*		.3	.37
BP
None	24	23	29
Mutated low IC50	6	20	14
Mutated intermediate IC50	7	0	14
Mutated high IC50	1	0	0
Mutated unknown IC50	1	0	0
P*		.7	.17

^*Comparing low versus intermediate mutation classes.